Horizon Discovery
has introduced a new platform for immuno-oncology research. The platform consists of several high-throughput assays that enable researchers to test thousands
of potential anticancer drugs that recruit the body’s own immune system to fight cancer.

Horizon’s new
platform enables researchers to study how new drugs are able to activate different types of immune cells as well as increase their ability to kill tumors.
The platform includes high-throughput ADCC, CDC, primary T cell activation, mixed lymphocyte reaction and T cell-mediated tumor lysis assays in 384-well
format, allowing researchers to test hundreds of new drugs simultaneously.